President Trump’s latest announcement on tariffs on generic pharmaceuticals sends an unmistakable message to the global marketplace: the era of assuming America will forever depend on foreign factories for essential medicines is over.
Read more Morning Greatness: Trump to Hold Cabinet Meeting at Camp David
The question isn’t whether America should bring more pharmaceutical manufacturing home. It absolutely should. The question is whether the timeline and supporting policies make that goal achievable.
At the moment, they don’t.
During the COVID-19 pandemic, Americans watched shortages of everything from antibiotics to basic hospital supplies while discovering just how dependent the United States had become on manufacturing thousands of miles away. A nation that can design the world’s most advanced fighter aircraft should never find itself wondering whether it can produce enough medicine during an emergency.
The administration deserves credit for recognizing that rebuilding industrial capacity requires more than speeches. President Trump has already demonstrated that investment follows leadership. This year, SelectUSA attracted a record $139 billion in investment into American manufacturing and advanced industries thanks to President Trump’s aggressive negotiations.
One of the biggest success stories has come from an often overlooked but enormously important partner: India.
Working closely with Ambassador Sergio Gor, whose energetic economic diplomacy has helped strengthen one of America’s most important strategic relationships, Indian companies announced more than $20 billion in planned U.S. investments during the SelectUSA Investment Summit. Much of that investment is centered on pharmaceutical manufacturing, research, and facilities that will create American jobs while strengthening domestic supply chains.
India is already a critical partner in America’s medicine supply, operating dozens of facilities nationwide that employ thousands of Americans on top of its role as a major trading partner.
Reshoring does not have to mean isolation. America’s closest democratic partners—India, the European Union, South Korea, and Japan—should be encouraged to invest in American production. When trusted allies build factories in Ohio, North Carolina, Texas, Indiana, or Pennsylvania, America gains manufacturing capacity, workers gain good-paying jobs, and global supply chains become dramatically more secure.
But building a modern pharmaceutical manufacturing facility is not like leasing warehouse space. Companies must secure land, navigate environmental reviews, obtain permits, construct specialized clean-room facilities, and complete extensive FDA inspections before a single bottle reaches pharmacy shelves.
Even under ideal circumstances, that process often stretches well beyond the two years currently outlined under President Trump’s tariff announcement.
Then comes another reality policymakers cannot ignore: electricity.
Large pharmaceutical campuses require enormous amounts of reliable power. In many parts of the country, utilities are already warning of transmission constraints and lengthy interconnection delays for major industrial projects. Manufacturers cannot produce lifesaving medicines without dependable energy infrastructure.
Read more The Fall of the ACLU
If America wants factories, it must also build the capacity to power them. That means permitting reform must be an essential component of the president’s agenda for medicine.
Congress and the administration have an opportunity to pair the President’s tariff strategy with expedited permitting for strategic manufacturing, accelerated environmental reviews, tax incentives for domestic construction, workforce development, and regulatory certainty that allows companies to invest confidently.
There is another obstacle that deserves equal attention. Even if manufacturers spend billions building American facilities, many generic drug companies still operate inside a marketplace where pharmacy benefit managers and group purchasing organizations exert extraordinary pricing pressure. Margins are squeezed so tightly that manufacturers often struggle to justify expanding production even when demand exists.
Asking companies to build expensive domestic plants while leaving those market distortions untouched risks creating a business model that simply doesn’t work. Reshoring production and reforming the generic drug marketplace must happen together.
There is also the question of what happens when the tariff clock expires. A 100 percent tariff followed by 200 percent duties will change purchasing behavior. But if sufficient domestic capacity has not yet come online, those costs do not disappear. They eventually find their way into hospitals, community pharmacies, rural health systems, insurers, employers, and ultimately patients.
It also ends up reducing competition to benefit a few companies at the expense of everyone else. The ones hit hardest will be seniors on fixed incomes, rural hospitals on razor-thin budgets, veterans, and working families managing chronic conditions that depend on affordable generic medications.
Fortunately, there is a path that advances the president’s goal without creating unnecessary disruption.
Keep the pressure on companies that refuse to invest in America. Reward those that commit to building here. Expand partnerships with trusted partners that are already investing billions in American production. Accelerate permitting. Modernize energy infrastructure. Reform the reimbursement system that discourages domestic manufacturing. And provide carefully tailored transition mechanisms where genuine shortages threaten patient access.
If Washington gets the details right, the United States won’t simply import less. It will once again become the country where the world’s safest, most reliable, and most affordable medicines are made.
Read more AI Will Save the U.S. Economy
